H. Mistry

The search for surrogacy in patient derived xenograft mouse trials: glass is less than half full

The paper evaluates the surrogacy of tumour burden biomarkers in preclinical xenograft trials and finds they poorly capture treatment effects on disease progression.

Evolutionary Based Adaptive Dosing Algorithms: Beware the Cost of Cumulative Risk

This study shows that adaptive dosing algorithms, which cycle treatment based on tumour burden, may lead to worse outcomes than continuous dosing when cumulative risk is considered.

Cardiac toxicity predictions: Safety pharmacologists correlate with the CiPA model

This study shows that safety pharmacologists can predict cardiac toxicity risks using a linear model, achieving strong correlation with a complex biophysical model.

Analysis of patient derived xenograft studies in Oncology drug development: impact on design and interpretation of future studies

This paper compares model-based analysis and un-paired t-test for PDX xenograft studies, finding model-based methods more powerful and capable of detecting smaller treatment effects.

Complex versus simple models: ion-channel cardiac toxicity prediction

This study compares predictive performance of complex cardiac models with a simple linear model for ion-channel toxicity, finding the simple model often performs as well or better.

Heterogeneity in the tumour size dynamics differentiates Vemurafenib, Dabrafenib and Trametinib in metastatic melanoma

This study uses a mathematical model to analyze tumor size dynamics in metastatic melanoma patients treated with Vemurafenib, Dabrafenib, and Trametinib, revealing differences in tumor shrinkage and resistance development.